Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants With Alzheimer's Disease Dementia

NCT07284472 is registered in ClinicalTrials.gov with Exciva GmbH as lead sponsor.

NCT NCT07284472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants With Alzheimer's Disease Dementia
Lead sponsor
Exciva GmbH
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 2, 2026
Completion date
February 28, 2029
Enrollment
300 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

agitation associated with alzheimer's disease dementia